What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.23%Below 5Y avg (0.27%)
Annual Rate
CNY 0.04Paid annual
Payout Ratio
11.8%Sustainable
Last Ex-Dividend
Jun 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.05BCNY
1.21B · vs all stocks (USD)
Updated Oct 24, 2026
Trailing P/E
48.38x
vs Biotechnology peers
Updated Oct 24, 2026
Revenue (TTM)
2.28BCNY
342.46M · vs all stocks (USD)
Updated Oct 24, 2026
Profit Margin
6.63%
vs Biotechnology peers
Updated Oct 24, 2026
Beta
0.6880x
vs all stocks
Updated Oct 24, 2026
52-Week Change
33.45%
vs all stocks
Updated Oct 24, 2026
Market Capitalization
8.05BCNY
1.21B · vs all stocks (USD)
Updated Oct 24, 2026
Enterprise Value
6.21BCNY
930.99M · vs all stocks (USD)
Updated Oct 24, 2026
Trailing P/E
48.38x
vs Biotechnology peers
Updated Oct 24, 2026
Forward P/E
32.25x
vs Biotechnology peers
Updated Oct 24, 2026
Price to Sales (TTM)
3.53x
vs Biotechnology peers
Updated Oct 24, 2026
Price to Book (MRQ)
2.92x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to Revenue
2.72x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to EBITDA
24.85x
vs Biotechnology peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 28.91×.Updated Oct 24, 2026
Gross Margin
41.89%
vs Biotechnology peers
Updated Oct 24, 2026
Profit Margin
6.63%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Margin
4.59%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Assets (TTM)
2.32%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Equity (TTM)
5.88%
vs Biotechnology peers
Updated Oct 24, 2026
Revenue (TTM)
2.28BCNY
342.46M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue per Share (TTM)
5.75CNYUpdated Oct 24, 2026
Quarterly Revenue Growth
3.60%
vs Biotechnology peers
Updated Oct 24, 2026
Gross Profit (TTM)
979.93MCNY
146.97M · vs all stocks (USD)
Updated Oct 24, 2026
EBITDA (TTM)
214.73MCNY
32.21M · vs all stocks (USD)
Updated Oct 24, 2026
Net Income (TTM)
151.34MCNY
22.70M · vs all stocks (USD)
Updated Oct 24, 2026
Quarterly Earnings Growth (YoY)
-24.90%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Cash Flow (TTM)
355.14MCNY
53.26M · vs all stocks (USD)
Updated Oct 24, 2026
Levered Free Cash Flow (TTM)
251.00MCNY
37.65M · vs all stocks (USD)
Updated Oct 24, 2026
Trailing Annual Dividend Rate
0.0450CNYUpdated Oct 24, 2026
Trailing Annual Dividend Yield
0.23%
vs all stocks
Updated Oct 24, 2026
5-Year Average Dividend Yield
0.27%
vs all stocks
Updated Oct 24, 2026
Payout Ratio
11.84%
vs Biotechnology peers
Updated Oct 24, 2026
Minority Interest (Equity)
28.36MCNYFY2025 · Dec 31, 2025
Revenue
2.21BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
1.27BCNYFY2025 · Dec 31, 2025
Gross Profit
939.76MCNYFY2025 · Dec 31, 2025
Operating Income
191.64MCNY
28.74M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
192.91MCNYFY2025 · Dec 31, 2025
Income Tax Expense
21.43MCNYFY2025 · Dec 31, 2025
Net Income
171.48MCNYFY2025 · Dec 31, 2025
EBIT
194.75MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
376.28MCNYFY2025 · Dec 31, 2025
Research & Development
159.93MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
175.34MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
5.03MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
6.24MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
1.84MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.4100CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.4100CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
407.19MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
407.19MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
171.48MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-4.54MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-43.80MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-147.78MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
475.49MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
171.48MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
-18.13MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-62.18MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-134.98MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-103.98MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-6.05BCNYFY2025 · Dec 31, 2025
Sale of Investments
6.05BCNYFY2025 · Dec 31, 2025
Other Investing Activity
-2.19MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-109.25MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-20.25MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-17.02MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-37.27MCNYFY2025 · Dec 31, 2025
Shares Outstanding
416.20MSharesUpdated Oct 24, 2026
Float Shares
136.73MSharesUpdated Oct 24, 2026
% Held by Insiders
66.66%
vs all stocks
Updated Oct 24, 2026
% Held by Institutions
6.19%
vs all stocks
Updated Oct 24, 2026
Total Cash (MRQ)
1.75BCNY
262.44M · vs all stocks (USD)
Updated Oct 24, 2026
Total Cash per Share (MRQ)
4.32CNYUpdated Oct 24, 2026
Total Debt (MRQ)
91.43MCNY
13.71M · vs all stocks (USD)
Updated Oct 24, 2026
Total Debt to Equity (MRQ)
0.0338x
vs Biotechnology peers
Updated Oct 24, 2026
Current Ratio (MRQ)
2.57x
vs Biotechnology peers
Updated Oct 24, 2026
Book Value per Share (MRQ)
6.62CNYUpdated Oct 24, 2026
Total Assets
3.94BCNY
591.29M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
2.92BCNYFY2025 · Dec 31, 2025
Total Liabilities
1.26BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
1.03BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
52.42MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
1.21BCNYFY2025 · Dec 31, 2025
Cash
472.96MCNYFY2025 · Dec 31, 2025
Cash Equivalents
8.58MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
481.54MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
1.29BCNYFY2025 · Dec 31, 2025
Accounts Receivable
600.02MCNYFY2025 · Dec 31, 2025
Inventory
294.68MCNYFY2025 · Dec 31, 2025
Accounts Payable
250.65MCNYFY2025 · Dec 31, 2025
Short-term Debt
35.06MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
2.21MCNYFY2025 · Dec 31, 2025
Long-term Debt
36.39MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
1.01MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
416.20MCNYFY2025 · Dec 31, 2025
Retained Earnings
1.10BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.68BCNY
402.13M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
144.16MCNYFY2025 · Dec 31, 2025
52-Week Low
11.46CNYUpdated Oct 24, 2026
52-Week High
23.43CNYUpdated Oct 24, 2026
52-Week Change
33.45%
vs all stocks
Updated Oct 24, 2026
Beta
0.6880x
vs all stocks
Updated Oct 24, 2026
50-Day MA
17.08CNYUpdated Oct 24, 2026
200-Day MA
14.94CNYUpdated Oct 24, 2026
Avg 10-Day Volume
25.55MSharesUpdated Oct 24, 2026
Avg 30-Day Volume
20.20MSharesUpdated Oct 24, 2026
Diluted EPS (TTM)
0.4000CNYUpdated Oct 24, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.42Profit Margin: 0.07
Financial Health
Altman Z-Score 5.47: safe zoneNotable
Altman Z-Score: 5.47
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.21B, above the global median of $1.14BNotable
Market cap (USD): 1,207,859,430.6Global Median: 1,137,180,293.291
Levered free cash flow is $37.65M, above the global median of $18.58MNotable